News

2026-08-06

Material Information- Announcement of the newly appointed Chief Business Officer

1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development officer, internal audit officer, or designated and non-designated representatives):Chief Business Officer 2.Date of occurrence of the change:2026/08/06 3.Name,

2026-08-06

Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers

1.Date of the board of directors resolution:2026/08/06 2.Name and title of the managerial officer with permission to engage in competitive conduct: (1)KC Sung/ Chief Technology Officer (2)Qiao Li/ Chief Operating Officer of the subsidiary 3.Items of competitive conduct in which the officer is permitted to engage: (1)KC Sung: Executive Director

2026-08-06

Material Information- Announcement of the Board’s Resolution to redeem and cancel treasury shares for a capital reduction and the record date

1.Date of the board of directors resolution:2026/08/06 2.Reason for capital reduction:Cancellation of the Company's second treasury share repurchase in 2026 in accordance with Article 28-2 of the Securities and Exchange Act. 3.Amount of capital reduction:NTD 40,000,000 4.Cancelled shares:4,000,000 shares 5.Capital reduction ratio:2.35% 6.Share capital after capital reduction:165,981,900 shares 7.Scheduled date of

2026-08-06

Material Information- Announcement on behalf of Handa Pharma, Inc. Increase captial to Handa Oncology, LLC

1.Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated,e.g., dividend yield, etc.):Handa Oncology, LLC equity 2.Date of occurrence of the event:2026/08/06 3.Date of the Board of Directors’ resolution:2026/08/06 4.Other approval date:None 5.Volume, unit price, and total monetary amount

2026-08-06

Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q2.

1.Date of the board of directors submitted or approved:2026/08/06 2.Date of the audit committee approved:2026/08/06 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): 2026/01/01~2026/06/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):421,566 5.Gross profit (loss) from operations accumulated

2026-08-03

Material Information- The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities

1.Date of institutional investor conference:2026/08/07 2.Time of institutional investor conference:14:30 3.Location of institutional investor conference:2F., No. 35, Sec. 1, Chang’an E. Rd., Zhongshan Dist., Taipei City 4.Outline of institutional investor conference: (1)The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities, to

2026-07-30

Material Information- Announces on Behalf Handa Oncology, LLC, regarding the 505 (b)(2) new formulation drug HND-039 OMCAZIO receives U.S. FDA Tentative Approval (TA)

1.Date of occurrence of the event: 2026/07/30 2.Company name:Handa Oncology, LLC 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Subsidiaries 4.Reciprocal shareholding ratios: Handa Oncology, LLC is a 100% indirectly owned subsidiary of the Company. 5.Cause of occurrence: Handa Oncology, LLC, a subsidiary of the Company, is developing a

2026-07-29

Material Information- Announcement of the expected date of the Board Meeting to approve 2026 Q2 Financial Report on August 6, 2026

1.Date of a notice of the board of directors meeting is issued:2026/07/29 2.Expected date of the board of directors meeting is convened:2026/08/06 3.Expected year and quarter of the financial reports or the annual self-assessed financial information submitted to the board of directors or approved by the board

2026-07-15

Material Information- Correction to Handa Pharmaceuticals, Inc., and on behalf of the subsidiary, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit

1.Parties to the legal matter: Plaintiff：Exelixis, Inc Defendant：Handa Pharmaceuticals, Inc., Handa Pharma, Inc. and Handa Oncology, LLC 2.Name of the court or punishing agency of the legal matter:United States District Court for DELAWARE 3.Reference/Case number of relevant documents of the legal matter:NO. 1:26-cv-00813-UNA 4.Date of occurrence of the event:2026/07/15 5.Details of

2026-07-08

Material Information- Announces Handa Pharmaceuticals, Inc., and on behalf of the subsidiary, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit

1.Parties to the legal matter: Plaintiff：Exelixis, Inc Defendant：Handa Pharmaceuticals, Inc., Handa Pharma, Inc. and Handa Oncology, LLC 2.Name of the court or punishing agency of the legal matter:United States District Court for DELAWARE 3.Reference/Case number of relevant documents of the legal matter:NO. 1:99-mc-09999 4.Date of occurrence of the event:2026/07/08 5.Details of